One or more of the required application components couldn’t be loaded. Please, refresh the page.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
10:04 AM
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PSTV

Plus Therapeutics Inc

Last Close
Mar 14 • 09:49AM ET
0.6300
Dollar change
-0.1201
Percentage change
-16.01%
Healthcare • Biotechnology • USA • NASD
Dividends
Earnings
Revenue
Forecast

Data

Timeframe

Next report dateFeb 14, 2025 (Est)
Report periodQ4 2024
EPS Est.-$0.40
GAAP EPS Est.-$0.40
Revenue Est.$2.60M

EPS Performance and Forecast

-2.40-1.80-1.20-0.600.00
Currency: USDQ4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
-2.25-2.06-1.73-0.88-1.07-1.09-0.53-0.56-0.40-0.34-0.31-0.34
# of Analysts443342344333
-2.25-2.10-0.59-1.00-0.55-0.75-0.45-0.37————
0.00
-0.00%		-0.04
1.82%		1.14
-65.83%		-0.12
14.06%		0.52
-48.72%		0.34
-31.19%		0.08
-15.09%		0.19
-34.22%		————

GAAP EPS Performance and Forecast

-2.40-1.80-1.20-0.600.00
Currency: USDQ4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
-2.25-2.06-1.73-0.88-1.07-1.09-0.53-0.56-0.40-0.34-0.31-0.34
# of Analysts443342344333
-2.25-2.10-0.59-1.00-0.55-0.75-0.45-0.37————
0.00
-0.00%		-0.04
1.82%		1.14
-65.83%		-0.12
14.06%		0.52
-48.72%		0.34
-31.19%		0.08
-15.09%		0.19
-34.22%		————

Revenue Performance and Forecast

0.00650K1M2M3M
Currency: USDQ4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
1.48M733.30K1.05M1.86M1.42M1.70M1.70M1.47M2.60M1.73M1.73M1.17M
# of Analysts333332233333
151.00K506.00K1.90M1.24M1.27M1.68M1.28M1.46M————
-1.33M
-89.82%		-227.30K
-31.00%		847.00K
80.44%		-617.70K
-33.25%		-150.30K
-10.60%		-23.00K
-1.35%		-421.00K
-24.76%		-10.30K
-0.70%		————

Price Reaction to Earnings Reports

Report Date-3 Days-2 Days-1 DayOpenHighLowClose+1 Day+2 Days+3 Days+1 Week-1 Week
Nov 14, 2024 AMC
1.291.311.261.281.291.161.171.191.241.191.181.23
Q3 ‘24 (Sep ‘24)
PSTV %
+8.40%+1.55%-3.82%
+1.59%
+2.38%
-7.94%
-7.14%
+1.71%+4.20%-4.03%-1.67%-9.56%
RSI
43
SPY %
-0.31%+0.05%-0.64%-0.61%-0.53%-1.60%-1.28%+0.41%+0.37%+0.03%+0.31%+0.43%
Aug 14, 2024 AMC
1.411.491.421.481.481.381.401.361.601.551.431.55
Q2 ‘24 (Jun ‘24)
PSTV %
-2.76%+5.67%-4.70%
+4.13%
+4.13%
-2.82%
-1.41%
-2.86%+17.65%-3.13%-2.05%-1.27%
RSI
34
SPY %
+0.05%+1.64%+0.32%+1.06%+1.77%+0.94%+1.71%+0.22%+0.96%-0.16%-0.78%+2.31%
May 15, 2024 AMC
2.162.172.322.222.302.182.252.242.182.132.162.24
Q1 ‘24 (Mar ‘24)
PSTV %
0.00%+0.46%+6.91%
-4.31%
-0.86%
-6.03%
-3.02%
-0.44%-2.68%-2.29%-0.92%-1.32%
RSI
72
SPY %
+0.01%+0.46%+1.24%+0.02%+0.33%-0.23%-0.21%+0.14%+0.12%+0.25%-0.73%+0.58%
Mar 05, 2024 AMC
1.992.132.182.072.261.921.941.731.691.611.771.93
Q4 ‘23 (Dec ‘23)
PSTV %
+2.58%+7.04%+2.35%
-5.05%
+3.67%
-11.88%
-11.24%
-10.59%-2.31%-4.73%0.00%-0.52%
RSI
62
SPY %
+0.94%-0.11%-1.00%+0.66%+0.96%+0.24%+0.51%+0.99%-0.60%-0.09%-0.16%-0.13%
Oct 31, 2023 AMC
1.071.101.221.321.361.221.291.361.601.611.591.01
Q3 ‘23 (Sep ‘23)
PSTV %
-0.93%+2.79%+10.92%
+8.20%
+11.48%
0.00%
+5.74%
+5.43%+17.65%+0.31%-6.47%-7.34%
RSI
47
SPY %
-0.45%+1.20%+0.63%+0.24%+1.27%+0.11%+1.07%+1.92%+0.91%+0.23%+0.07%-1.44%
Aug 14, 2023 AMC
3.162.502.502.592.592.252.432.392.332.332.332.64
Q2 ‘23 (Jun ‘23)
PSTV %
+8.68%-20.89%0.00%
+3.60%
+3.60%
-10.20%
-2.80%
-1.65%-2.51%0.00%+3.10%+1.15%
RSI
49
SPY %
+0.04%-0.06%+0.55%-0.41%-0.33%-1.30%-1.16%-0.73%-0.76%+0.05%-0.27%-0.43%
Apr 20, 2023 AMC
4.224.354.604.304.803.753.963.773.453.393.904.16
Q1 ‘23 (Mar ‘23)
PSTV %
+3.69%+3.20%+5.83%
-6.55%
+4.27%
-18.48%
-13.98%
-4.92%-8.41%-1.61%+2.12%+2.67%
RSI
59
SPY %
+0.07%-0.02%-0.55%+0.08%+0.19%-0.42%+0.08%+0.10%-1.59%-0.42%+0.85%-0.24%
Feb 23, 2023 AMC
5.485.825.885.425.935.425.485.665.104.805.225.82
Q4 ‘22 (Dec ‘22)
PSTV %
+0.97%+6.30%+1.03%
-7.78%
+0.89%
-7.78%
-6.89%
+3.32%-9.79%-5.88%+5.61%-0.54%
RSI
50
SPY %
-2.01%-0.14%+0.53%-1.31%-0.85%-1.75%-1.07%+0.34%-0.37%-0.38%+1.60%-1.38%
Oct 20, 2022 AMC
7.357.327.207.207.206.846.986.906.826.677.357.83
Q3 ‘22 (Sep ‘22)
PSTV %
-6.77%-0.45%-1.60%
0.00%
0.00%
-5.00%
-3.13%
-1.08%-1.20%-2.22%+2.08%+2.47%
RSI
42
SPY %
+1.17%-0.71%-0.84%-0.08%+2.57%-0.51%+2.43%+1.22%+1.60%-0.75%+2.38%-2.28%
Jul 21, 2022 AMC
7.447.407.658.258.557.057.958.007.587.467.427.62
Q2 ‘22 (Jun ‘22)
PSTV %
+3.27%-0.56%+3.41%
+7.84%
+11.76%
-7.84%
+3.92%
+0.64%-5.32%-1.49%-2.17%-2.55%
RSI
44
SPY %
+2.70%+0.64%+1.02%+0.03%+0.35%-1.51%-0.93%+0.12%-1.18%+2.60%+1.46%+1.91%
Apr 21, 2022 AMC
13.2013.0813.2312.7512.8610.7311.1510.3810.2010.2010.0513.64
Q1 ‘22 (Mar ‘22)
PSTV %
+1.14%-0.90%+1.15%
-3.63%
-2.83%
-18.92%
-15.76%
-6.85%-1.78%+0.06%-1.92%-4.79%
RSI
35
SPY %
+1.61%-0.07%-1.50%-0.26%+0.01%-2.88%-2.74%+0.58%-2.90%+0.28%-3.70%-1.25%
Feb 24, 2022 AMC
15.1515.1515.1514.7015.4514.4015.4515.6016.5015.7514.9315.75
Q4 ‘21 (Dec ‘21)
PSTV %
-0.98%0.00%0.00%
-2.97%
+1.98%
-4.95%
+1.98%
+0.97%+5.77%-4.55%-9.51%0.00%
RSI
49
SPY %
-1.07%-1.77%+1.50%+0.31%+2.23%-0.10%+2.21%-0.26%-1.52%+1.84%-0.81%-2.14%
Daily change and RSI 14 are based on the report date for BMO releases and the following day for AMC releases.
63%
EPS beats the estimate
5/8 last quarters
63%
GAAP EPS beats the estimate
5/8 last quarters
13%
Revenue beats the estimate
1/8 last quarters

Latest Revisions

Estimate

Q3 ‘24
Estimate
-0.56
Up Revisions
0/4
Down Revisions
0/4
Revision Date
Nov 13, 2024
Q4 ‘24
Estimate
-0.43
Up Revisions
0/1
Down Revisions
0/1
Revision Date
Mar 13, 2025
FY ‘23
Estimate
-4.63
Up Revisions
0/4
Down Revisions
0/4
Revision Date
Feb 20, 2024
FY ‘24
Estimate
-2.21
Up Revisions
0/1
Down Revisions
0/1
Revision Date
Mar 13, 2025

Estimate Revisions

Period

AugSepOctNovDec24FebMarAprMayJunJulAugSepOctNovDec25FebMar-10.00-8.00-6.00-4.00-2.000.00● EPS Estimate0.000.651.301.952.603.25● Close Price
10123
Peers: ADAP SUPN KPTI IMUX MEIP PBYI CRIS RIGL SYBX
 | Held by: VXF
Scroll to Statements
Index- P/E- EPS (ttm)-2.24 Insider Own2.55% Shs Outstand5.90M Perf Week-59.87%
Market Cap3.71M Forward P/E- EPS next Y-1.49 Insider Trans7.35% Shs Float5.75M Perf Month-43.75%
Income-12.88M PEG- EPS next Q-0.40 Inst Own11.50% Short Float2.44% Perf Quarter-51.72%
Sales5.72M P/S0.65 EPS this Y54.36% Inst Trans5.93% Short Ratio0.02 Perf Half Y-53.33%
Book/sh-0.88 P/B- EPS next Y23.00% ROA-127.22% Short Interest0.14M Perf Year-64.41%
Cash/sh0.81 P/C0.78 EPS next 5Y29.07% ROE-522.50% 52W Range0.24 - 2.67 Perf YTD-45.22%
Dividend Est.- P/FCF- EPS past 5Y68.20% ROI- 52W High-76.41% Beta0.79
Dividend TTM- Quick Ratio0.44 Sales past 5Y474.41% Gross Margin85.99% 52W Low162.50% ATR (14)0.30
Dividend Ex-Date- Current Ratio0.44 EPS Y/Y TTM60.96% Oper. Margin-255.98% RSI (14)41.25 Volatility47.47% 40.20%
Employees20 Debt/Eq- Sales Y/Y TTM52.63% Profit Margin-225.07% Recom1.00 Target Price10.25
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q63.35% Payout- Rel Volume0.77 Prev Close0.75
Sales Surprise-0.70% EPS Surprise34.22% Sales Q/Q17.42% EarningsNov 14 AMC Avg Volume8.63M Price0.63
SMA20-37.04% SMA50-44.07% SMA200-55.77% Trades Volume643,180 Change-16.01%
Date Action Analyst Rating Change Price Target Change
Jan-25-21Initiated Ladenburg Thalmann Buy $8
Oct-16-20Initiated Maxim Group Buy $6
Mar-11-25 11:00AM
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
(ACCESSWIRE) +12.60%
Mar-10-25 07:30AM
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
(GlobeNewswire) -19.11%
Mar-07-25 01:49PM
Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday
(Insider Monkey) +9.03%
07:33AM
FDA ODD given to Plus Therapeutics injectable radiotherapy
(Pharmaceutical Technology)
07:30AM
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
(GlobeNewswire)
07:30AM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Mar-06-25 07:30AM
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
(GlobeNewswire) +311.43%
Mar-05-25 04:01PM
Plus Therapeutics Announces New Employment Inducement Grants
(GlobeNewswire) +15.82%
Mar-04-25 02:06PM
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
(GlobeNewswire) -54.21%
Feb-26-25 07:30AM
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
(GlobeNewswire) -29.63%
Feb-24-25 07:30AM
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
(GlobeNewswire) -5.00%
Feb-20-25 07:30AM
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
(GlobeNewswire)
Feb-18-25 07:30AM
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
(GlobeNewswire)
Dec-17-24 07:30AM
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
(GlobeNewswire) -8.55%
Dec-04-24 07:30AM
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
(GlobeNewswire)
Dec-03-24 07:30AM
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
(GlobeNewswire)
09:48AM Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
Nov-25-24 09:48AM
CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis
(Medical Device Network)
07:30AM
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
(GlobeNewswire)
Nov-22-24 07:30AM
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
(GlobeNewswire)
Nov-21-24 07:30AM
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
(GlobeNewswire)
Nov-15-24 02:16AM
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
(GuruFocus.com) -7.14%
Nov-14-24 04:15PM
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
(GlobeNewswire)
Nov-07-24 07:18AM
Plus Therapeutics partners with SpectronRx for CNS therapy development
(Pharmaceutical Business Review)
Nov-06-24 07:30AM
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
(GlobeNewswire) +5.15%
Nov-05-24 07:30AM
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
(GlobeNewswire)
Oct-29-24 07:30AM
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
(GlobeNewswire)
Oct-01-24 07:30AM
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
(GlobeNewswire) -10.27%
Sep-18-24 07:30AM
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
(GlobeNewswire)
Sep-04-24 07:30AM
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
(GlobeNewswire)
Aug-15-24 09:42AM
Q2 2024 Plus Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Aug-14-24 09:53PM
PSTV Stock Earnings: Plus Therapeutics Misses EPS, Misses Revenue for Q2 2024
(InvestorPlace)
04:16PM Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
04:16PM
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
(GlobeNewswire)
Aug-13-24 07:30AM
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
(GlobeNewswire) +5.67%
Aug-12-24 07:30AM
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
(GlobeNewswire)
Aug-08-24 07:30AM
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
(GlobeNewswire)
Jul-25-24 07:30AM
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
(GlobeNewswire)
Jul-02-24 07:30AM
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
(GlobeNewswire)
Jun-07-24 07:30AM
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
(GlobeNewswire) -5.24%
May-17-24 05:00PM
Plus Therapeutics Announces New Employment Inducement Grants
(GlobeNewswire)
May-16-24 03:05AM
Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
(GuruFocus.com)
May-15-24 08:53PM
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024
(InvestorPlace) +6.91%
04:15PM
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
(GlobeNewswire)
May-13-24 07:30AM
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
(GlobeNewswire)
May-09-24 11:29AM
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
(GlobeNewswire)
May-08-24 05:35PM
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
(GlobeNewswire) +6.57%
May-06-24 07:30AM
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
(GlobeNewswire) +11.67%
Apr-22-24 09:00AM
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
(Benzinga)
07:00AM
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
(GlobeNewswire)
Apr-09-24 07:00AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team
(GlobeNewswire)
Mar-27-24 08:00AM
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
(GlobeNewswire)
Mar-25-24 08:00AM
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
(GlobeNewswire)
Mar-11-24 07:00AM
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
(GlobeNewswire)
Mar-07-24 08:59AM
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
(Insider Monkey) -10.59%
Mar-06-24 01:43PM
Q4 2023 Plus Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) -11.24%
Mar-05-24 09:52PM
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
(InvestorPlace)
05:35PM
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
04:05PM
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
(GlobeNewswire)
Feb-27-24 08:00AM
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
(GlobeNewswire) +6.01%
Dec-18-23 07:00AM
Plus Updates Financial and Cash Guidance for 2024
(GlobeNewswire)
Dec-12-23 08:00AM
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
(GlobeNewswire)
Nov-29-23 08:00AM
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
(GlobeNewswire) -5.56%
Nov-20-23 07:00AM
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
(GlobeNewswire) -27.76%
Nov-15-23 07:00AM
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
(GlobeNewswire) +12.43%
Nov-13-23 09:31AM
Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?
(PR Newswire)
Nov-03-23 07:00AM
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
(GlobeNewswire) +17.65%
Nov-01-23 09:29AM
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2023 Earnings Call Transcript
(Insider Monkey) +5.74%
Oct-31-23 04:10PM
Plus Therapeutics Announces Share Repurchase Program
(GlobeNewswire) +10.92%
04:05PM
Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
(GlobeNewswire)
Oct-25-23 09:21AM
Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
(GlobeNewswire) -7.34%
Oct-23-23 04:05PM
Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
(GlobeNewswire) -5.22%
Oct-10-23 07:00AM
Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium ( Re) Obisbemeda in Leptomeningeal Metastases
(GlobeNewswire) +5.04%
Oct-09-23 07:00AM
Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October
(GlobeNewswire)
Sep-19-23 01:07PM
Targeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSE
(Exec Edge)
Sep-15-23 11:17AM
Director Howard Clowes Buys 6,993 Shares of Plus Therapeutics Inc
(GuruFocus.com)
Sep-11-23 12:44PM
Plus Therapeutics Presents Cancer Treatment Data at Conference
(Exec Edge) +8.70%
07:00AM
Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference
(GlobeNewswire)
Sep-08-23 12:49PM
Plus Therapeutics Expands Biocept Partnership with Diagnostic Platform
(Exec Edge) -53.54%
11:18AM
Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?
(Benzinga)
08:30AM
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers
(Benzinga)
07:00AM
Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay
(GlobeNewswire)
Sep-05-23 01:13PM
Plus Therapeutics Trialing Cancer Treatment for Cerebrospinal Fluid
(Exec Edge)
07:00AM
Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase
(GlobeNewswire)
Aug-30-23 07:00AM
Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-18-23 09:55AM
Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
(Zacks)
Aug-15-23 10:58AM
Q2 2023 Plus Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Aug-14-23 04:05PM
Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
(GlobeNewswire)
Aug-11-23 06:28PM
Positive Results Unveiled for Targeted CNS Cancer Treatment in Recent Study by Plus Therapeutics
(Exec Edge) -20.89%
08:00AM
EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer
(Benzinga)
06:30AM
Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference
(GlobeNewswire)
Aug-08-23 04:05PM
Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
(GlobeNewswire) +10.14%
11:22AM
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
(GlobeNewswire)
Aug-03-23 07:00AM
Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
(GlobeNewswire)
Jul-27-23 05:34PM
Plus Therapeutics Appoints Dr. Pius Maliakal as VP of Clinical Operations
(Exec Edge) -9.02% +5.17%
04:05PM
Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations
(GlobeNewswire)
07:00AM
Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference
(GlobeNewswire)
Jul-13-23 07:00AM
Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
(GlobeNewswire)
Jun-29-23 07:00AM
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT Clinical Trials at SNMMI Annual Meeting
(GlobeNewswire) -5.38%
Jun-14-23 07:00AM
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
(GlobeNewswire) -10.68%
Jun-08-23 07:00AM
Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting
(GlobeNewswire)
Jun-01-23 07:00AM
Plus Therapeutics Provides Company Update Today
(GlobeNewswire)
May-30-23 07:00AM
Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023
(GlobeNewswire) -7.19%
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Institutional Ownership

AIGH Capital Management LLC9.51%
GEODE CAPITAL MANAGEMENT, LLC0.99%
VANGUARD GROUP INC0.55%
TWO SIGMA SECURITIES, LLC0.25%
BlackRock, Inc.0.12%
Tower Research Capital LLC0.08%
OSAIC HOLDINGS, INC.0.00%
SBI Securities Co., Ltd.0.00%
BANK OF AMERICA CORP /DE/0.00%
GROUP ONE TRADING LLC0.00%
Income Statement • Balance Sheet • Cash Flow

Data

Timeframe

PeriodTTMFY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period End Date12/31/202312/31/202212/31/202112/31/202012/31/201912/31/201812/31/2017
Period Length12 Months12 Months12 Months
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.

Learn more
Total Revenue
5.724.910.22
Cost of Goods Sold Incl. D&A
0.800.740.71
Gross Profit
4.924.17-0.49
Selling, General and Administrative Excl. Other
19.5817.4919.22
Research and Development
11.199.699.70
Other Operating Expense
0.000.000.00
Operating Income
-14.65-13.32-19.71
Interest Expense
0.180.400.71
Unusual Expense
-5.650.00-0.00
Net Income Before Taxes
-12.88-13.32-20.27
Income Taxes
0.000.000.00
Consolidated Net Income
-12.88-13.32-20.27
Net Income From Continuing Operations
-12.88-13.32-20.27
Net Income
-12.88-13.32-20.27
EPS (Recurring)
-2.14-4.24-11.58
EPS (Basic, Before Extraordinaries)
-2.42-4.24-11.58
EPS (Diluted)
-2.24-4.24-11.58
EBITDA
-13.85-12.58-19.00
Price To Earnings Ratio
-0.34-0.34-0.28
Price To Sales Ratio
2.001.1237.16
Gross Margin
85.9984.84-217.86
Operating Margin
-255.98-271.14-8,800.00
Net Margin
-225.07-271.04-9,051.34
Shares Outstanding
5.904.522.24
Market Capitalization
4.424.427.92
values in Millions, USD
Insider Trading Volume
MarAprMayJunJulAugSepOctNovDec25FebMar0.0025.00K50.00K75.00K100.00KUSD Trades Volume$0.00$0.65$1.30$1.95$2.60● Close Price
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hawkins Richard JDirectorSep 13 '24Buy1.504,0005,99615,188Sep 17 07:00 AM
Hawkins Richard JDirectorSep 12 '24Buy1.356,2858,51211,188Sep 16 07:00 AM
Petersen GregDirectorSep 11 '24Buy1.3512,50016,87548,921Sep 13 06:04 AM
Clowes HowardDirectorSep 11 '24Buy1.345,0006,68126,497Sep 13 06:04 AM
HEDRICK MARC HChief Executive OfficerSep 10 '24Buy1.238,0009,83920,425Sep 11 06:02 AM
Sims Andrew John Hugh MacIntyrChief Financial OfficerSep 10 '24Buy1.274,0985,2049,815Sep 11 06:02 AM
Sims Andrew John Hugh MacIntyrChief Financial OfficerMay 08 '24Buy2.044,90210,0005,717May 10 07:30 AM
HEDRICK MARC HChief Executive OfficerMay 08 '24Buy2.0412,25525,00012,425May 10 07:30 AM
Petersen GregDirectorMay 08 '24Buy2.0412,25525,00036,421May 10 07:30 AM
Clowes HowardDirectorMay 08 '24Buy2.049,80420,00021,497May 10 07:30 AM
Hawkins Richard JDirectorMay 08 '24Buy2.044,90210,0004,903May 10 07:30 AM
Lenk Robert PDirectorMay 08 '24Buy2.044,1678,50129,327May 10 07:30 AM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.